Abortion pill reversal: What the science actually says

Heartbeat International made headlines this week announcing that more than 8,000 women have used its Abortion Pill Rescue Network in an attempt to continue their pregnancies after starting the chemical abortion process. Democrats and major medical groups say the procedure is scientifically unsound. Pro-life advocates say the results speak for themselves.

So who’s right — and what does the science actually show?

The answer, as is often the case in medicine, is more complicated than either side’s talking points suggest.

How the abortion pill actually works

To understand the debate, it helps to understand the drugs involved. A chemical abortion — now responsible for about 63% of all clinician-provided abortions in the United States, according to the most recent Guttmacher Institute data — uses a two-drug sequence.

The first drug, mifepristone, works by blocking progesterone, a hormone the body naturally produces to sustain a pregnancy. Without progesterone doing its job, the pregnancy stops developing. A day or two later, a second drug, misoprostol, triggers uterine contractions to complete the process.

---

SEE ALSO: Pro-life group says abortion-pill reversal saved 8,000 pregnancies

---

The “reversal” protocol, developed by pro-life physicians, is based on a straightforward theory: If mifepristone works by blocking progesterone receptors, administering supplemental progesterone quickly enough might outcompete the drug and allow the pregnancy to continue.

Timing appears central. Heartbeat International says the best outcomes occur when progesterone is administered within 24 hours of taking mifepristone, though it reports some continued pregnancies beyond that window.

Progesterone itself is not an obscure drug. It is widely used in certain pregnancy-support contexts — including some fertility treatments and in specific subgroups of women at elevated risk of miscarriage — though evidence of benefit varies depending on the clinical situation. Supporters argue that this long track record makes the reversal protocol a logical extension of established medicine rather than an inherently experimental gamble.

What the research shows — and where it falls short

The scientific dispute centers on a limited and methodologically uneven body of research.

One of the foundational papers frequently cited by proponents is a 2018 peer-reviewed case series published in Issues in Law & Medicine. The study reported outcomes for 754 women who received progesterone after taking mifepristone but before misoprostol. The authors reported reversal rates that varied by regimen, including higher success rates with certain intramuscular and high-dose oral protocols.

Critics point out, however, that the study did not include a concurrent control group. Instead, it compared outcomes to historical estimates of continuing pregnancy after mifepristone alone. Without a randomized comparison group of women who took mifepristone and received no treatment, it is difficult to determine how much of the observed continuation rate was attributable to progesterone rather than natural variability.

That uncertainty matters because mifepristone alone does not always result in a completed abortion, which is one reason misoprostol is part of the standard two-drug protocol.

A more rigorous attempt to test the reversal theory came in the form of a small randomized controlled trial — the gold standard in medical research — published in 2020. The trial was halted early after bleeding events occurred in participants in both the progesterone and placebo groups. Because enrollment stopped prematurely, the study was too small to draw reliable conclusions about effectiveness. The safety concerns and early termination have since been cited by critics as evidence that the protocol should not be offered outside formal research settings.

In 2024, a systematic review published in BMJ Sexual & Reproductive Health examined the available human studies. The review identified 561 individuals who received progesterone after mifepristone; 271, or 48%, had ongoing pregnancies. However, the authors concluded that, based on mostly low-quality evidence, the ongoing pregnancy rate did not appear significantly higher than what has been observed with mifepristone alone. The review characterized the overall evidence base as weak and called for more rigorous research.

Preclinical research has also entered the debate. A 2023 animal study published in Scientific Reports reported that progesterone appeared to reverse mifepristone’s effects in a rat model under controlled conditions. The authors cautioned that animal findings do not automatically translate to humans but suggested further study was warranted.

A small Australian pilot study also published in 2023 explored an oral progesterone protocol for women who changed their minds after taking mifepristone, describing it as a potentially low-risk option meriting additional investigation. Like other studies in this area, however, it was limited in size.

Where the institutions stand

Major U.S. medical organizations have taken clear positions. The American College of Obstetricians and Gynecologists states that so-called “medication abortion reversal” is not supported by reliable scientific evidence and should not be recommended to patients. ACOG has also argued that state laws requiring physicians to inform patients about the option constitute political interference in the practice of medicine. Other prominent medical organizations, including the American Medical Association, have similarly criticized such mandates.

Heartbeat International and affiliated physicians reject that characterization. They argue that progesterone has an established safety profile in pregnancy care, that thousands of documented continued pregnancies through the network represent meaningful real-world evidence, and that women who regret taking mifepristone deserve access to possible options rather than being told nothing can be done.

The core dispute

The most honest summary is this: The existing research is not strong enough to definitively settle the argument.

Critics are correct that the evidence base is thin, that key studies lack control groups, that the only randomized trial was stopped early, and that leading medical institutions do not endorse the protocol.

Proponents are correct that the absence of definitive proof is not the same as proof of ineffectiveness, that mifepristone alone does not uniformly end pregnancies, and that the biological rationale behind progesterone administration is not implausible.

What remains missing is a large, well-designed clinical trial with a proper control group and sufficient statistical power to assess both effectiveness and safety. Given the political and ethical complexities surrounding abortion research, conducting such a trial has proven difficult.

Until stronger evidence emerges, the debate over abortion pill reversal will likely continue — driven as much by values and policy judgments as by unsettled science.